Immuron Limited (ASX:IMC)

Market Cap	14.53M -39.1%
Revenue (ttm)	7.71M +5.9%
Net Income	-3.68M
EPS	-0.01
Shares Out	322.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,447
Open	0.0400
Previous Close	0.0450
Day's Range	0.0400 - 0.0450
52-Week Range	0.0260 - 0.0980
Beta	0.47
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About Immuron

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IMC

Financial Performance

In fiscal year 2026, Immuron's revenue was 7.71 million, an increase of 5.85% compared to the previous year's 7.29 million. Losses were -3.68 million, -29.45% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error